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Systemic Toxoplasmosis
Post Allogeneic Stem
Cell Transplantation
(Allo-SCT): Lessons
Learned from HIV?
A 51-year-old woman with Imatinib-resistant
chronic myelogenous leukemia underwent a reduced-
intensity allogeneic-stem cell transplant (Allo-SCT)
conditioned with ﬂudarabine 150 mg/m2, melphalan
140 mg/m2 and alemtuzumab 100 mg from an unre-
lated donor. The graft was unmanipulated and con-
tained 8.3  106 cells/kg CD34 cells. The patient
was seropositive for cytomegalovirus (CMV), Epstein-
Barr virus (EBV), and toxoplasmosis and seronegative
for HBV, HCV, and HIV. The HLA-matched donor
was seropositive for CMV and EBV and seronegative for
HBV, HCV, HIV, and toxoplasmosis. There was
prompt engraftment (neutrophils 0.5  109/L and
platelets 20  109/L on days 15 and 12, respec-
tively) complicated by acute gastrointestinal graft-
versus-host disease (GVHD) grade II responsive to
high-dose prednisolone. Full donor multilineage
lympho-hematopoietic chimerism was achieved by
day 60 and the patient was clinically well on a ste-
roid dose-tapering program. Antimicrobial prophy-
laxis included oral cotrimoxazole 480 mg once daily
for 7 days immediately prior to day 0 and from day
28 onward.
The patient’s course post-Allo-SCT was com-
plicated by 5 episodes of CMV reactivation as well
as graft failure without evidence of disease recur-
rence from day 140 onward. In view of pancyto-
penia, cotrimoxazole was stopped, and she received
granuloctye-colony stimulating factor (G-CSF)
support. On day 270 the patient was readmitted
with fever and symptoms of sepsis. Despite imme-
diate broad-spectrum antimicrobial treatment, she
deteriorated rapidly with progressive septic shock
and multiorgan failure, and died despite intensive
care support 3 days after readmission. Histology of
samples obtained at autopsy from the lung, the
heart, and the bone marrow revealed disseminated
toxoplasmosis (Figure 1). Immune-reconstitution
studies revealed poor reconstitution of CD4 T
cells (see Figure 2).
Disseminated toxoplasmosis is a rare complica-
tion of Allo-SCT. As the prevalence of seropositiv-
ity for toxoplasmosis is variable among countries,
toxoplasmosis after Allo-SCT has been reported to
occur in 1% in Britain but in 5% in France [1].
Although eliciting an antibody response, the caus-
ative intracellular parasite, Toxoplasma gondii, is
controlled predominantly by the cellular immune
response with a vital role for T cells and Th1
cytokines [2]. Patients who receive alemtuzumab as
in vivo T cell depletion or who are seropositive
recipients of seronegative cells are particularly at
risk of toxoplasmosis reactivation [3]. Nonetheless,
no consensus regarding screening the donor recip-
ient pair for toxoplasmosis serostatus prior to trans-
plantation has been reached [4] and a European
Group for Blood and Marrow Transplantation sur-
vey conﬁrmed that 50% of participating centers
routinely determined toxoplasmosis serology in re-
cipients or donors [5]. This is in contrast with
practice in the setting of HIV: The Infectious Dis-
ease Society of America recommends toxoplasma
screening for all HIV patients and prophylaxis is
advised depending on CD4 levels: if the CD4
cells are 100/L, all patients should receive cot-
rimoxazole or alternatively dapsone-pyrimethamine or
atovaquone [6]. Interestingly, our patient had CD4
levels 100/ML throughout the whole course after
the transplantation (Figure 2). Also of note, when the
patient’s condition worsened, she did not take any
regular prophylaxis against Toxoplasma gondii. There-
Figure 1. Autopsy ﬁndings: parasites in the bone marrow (A), parasites in cardiomyocytes (B), and parasites in the lung (C) (H&E 150).
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fore, this case illustrates the need to assess toxoplas-
mosis serology pretransplant and to use effective pro-
phylaxis. The analogous situation in HIV patients
suggests that absolute levels of lymphocyte subsets
may be of value in determining the duration of pro-
phylaxis in Allo-SCT patients.
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Treatment of Severe
Hemorrhagic Cystitis after
Allogeneic Stem Cell
Transplantation with
Palifermin, a Recombinant
Human Keratinocyte
Growth Factor
Hemorrhagic cystitis (HC) is common after high-
dose therapy and allogeneic stem cell transplantation
[1,2]. The severity of this complication ranges from
asymptomatic macrohematuria to excessively painful
and sometimes life-threatening bleeding. Direct tox-
icity from cytotoxic agents like cyclophosphamide and
reactivation of a latent infection with polioma or ad-
enovirus during episodes of profound immunosup-
pression are supposed to be involved in its pathogen-
esis [3,4]. Once diagnosis has been made, the
treatment of hemorrhagic cystitis is polypragmatic
and often ineffective.
Palifermin is a recombinant human keratinocyte
growth factor (KGF), a member of the ﬁbroblast
growth factor (FGF) family, which binds speciﬁcally
to the human KGF receptor and induces proliferation
and differentiation of epithelial cells, including gas-
trointestinal epithelial cells, hepatocytes, type II pneu-
mocytes, and transitional urothelial cells [5]. It has
been approved for prophylaxis of oral and gastrointes-
tinal mucositis in the context of high-dose therapy and
autologous as well as allogeneic stem cell transplanta-
tion [6]. We here describe the ﬁrst successful treat-
ment of severere hemorrhagic cystitis with Palifermin.
A-24-year old man suffered from refractory T-
acute lymphoblastic leukemia (ALL). He achieved a
ﬁrst remission after experimental treatment with
Ara-G, and received an allogeneic stem cell transplant
from an unrelated donor following conditioning with
Fludarabine, high-dose Cytarabine, Amsacrine, and
total body irradiation (TBI) (12 Gy). The early clinical
course was uneventful and the patient had hematopoi-
etic reconstitution of white blood cells (WBC) on day
14. The patient’s blood was weekly screened for
cytomegalovirus (CMV), Ebstein-Barr virus (EBV),
adenovirus, herpes simplex virus type-1 and -2, human
herpes virus 6, and BK-virus (BKV) infections with all
negative results. Twenty-ﬁve days after transplanta-
tion, he developed acute graft-versus-host disease
(aGVHD) III grade of the skin and gastrointestional
(GI) tract, which responded to combined therapy with
steroids and basiliximab. Steroids could be discontin-
ued on day 33 with resolving of GVHD of the GI
Figure 2. Lymphocyte subsets over time.
Letters to the Editor872
